The Los Angeles Post
U.S. World Business Lifestyle
Today: March 29, 2025
Today: March 29, 2025

Novo says Ozempic to be eligible for US price negotiations in less than a year

FILE PHOTO: Ozempic pens sit on a production line at Novo Nordisk's site in Hillerod
September 23, 2024
Reuters - Reuters

(Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.

Jorgensen is set to testify before a Senate committee on Tuesday in a hearing focused on U.S. prices for its widely popular Ozempic and weight-loss drug Wegovy.

WHY IT'S IMPORTANT

The comments confirm what Wall Street analysts have been saying: that the 2027 list of price negotiations will include Novo's Ozempic. Last week, another executive from Novo had said at an industry conference that Ozempic would "very likely" be on the 2027 list. The list will be announced in February of 2025.

BY THE NUMBERS

A month's supply of Ozempic has a U.S. list price of $935.77, while Wegovy lists for $1,349.02 per month, according to the drugmaker's website, although most consumers pay less based on their insurance plans.

CONTEXT

The Inflation Reduction Act of 2022 allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health program, which covers millions of Americans aged 65 and older as well as the disabled.

Novo's Ozempic and weight-loss drug Wegovy, both hugely popular drugs, have faced criticism from lawmakers over their high prices in the United States.

Jorgensen said in his written testimony that the net price of Ozempic - the amount that Novo is actually paid for the medicine - has declined by about 40% since its introduction in the United States, and the net price of Wegovy has similarly declined since its launch less than three years ago.

He added that under current market conditions, Novo expects that net prices will continue to decline for both Ozempic and Wegovy.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)

Related Articles

Wegovy diet plan: What foods to eat and avoid while taking semaglutide Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings
Share This

Popular

Business|Political|Technology|US

Musk to visit CIA on Monday, spokesperson says

Musk to visit CIA on Monday, spokesperson says
Business|Political|US

Judges block Trump orders targeting two law firms as Skadden cuts deal

Judges block Trump orders targeting two law firms as Skadden cuts deal
Arts|Business|Economy|Entertainment|Travel

What to know about Boulder, Colorado, the Sundance Film Festival's new home

What to know about Boulder, Colorado, the Sundance Film Festival's new home
Business|Crime|Political|US

Trump commutes the sentence of Ozy Media co-founder Carlos Watson in financial conspiracy case

Trump commutes the sentence of Ozy Media co-founder Carlos Watson in financial conspiracy case

Economy

Business|Economy|Technology|US

Musk's xAI buys Musk's X social media platform for $33 billion

Musk's xAI buys Musk's X social media platform for $33 billion
Business|Economy|Political|US

Trump says he is willing to make deals on tariffs

Trump says he is willing to make deals on tariffs
Business|Celebrity|Economy|Science|Technology

Elon Musk sells X to his own xAI for $33 billion in all-stock deal

Elon Musk sells X to his own xAI for $33 billion in all-stock deal
Americas|Business|Economy|Finance|Political

Brazil's Lula will not take unorthodox measures ahead of election, minister says

Brazil's Lula will not take unorthodox measures ahead of election, minister says

Access this article for free.

Already have an account? Sign In